SynAct Pharma
Synact Pharma: Q3 review (Redeye)

2019-11-15 15:45
Earlier today, Synact reported its figures for the third quarter. The report included no surprises, and the ongoing Phase II study with AP1189 in RA seems to progress according to plan. We continue to expect interim data readout from the first part of the study during Q1 2020.

info@redeye.se (Redeye.se)
Redeye AB - Redeye.se

SynAct Pharma - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -